Goldman Sachs’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-160,000
| Closed | -$13.6M | – | 6639 |
|
|
2025
Q4 | $13.6M | Buy |
160,000
+137,500
| +611% | +$11.3M | ﹤0.01% | 2757 |
|
|
2025
Q3 | $1.75M | Hold |
22,500
| – | – | ﹤0.01% | 4594 |
|
|
2025
Q2 | $1.76M | Hold |
22,500
| – | – | ﹤0.01% | 4274 |
|
|
2025
Q1 | $1.63M | Sell |
22,500
-12,500
| -36% | -$895K | ﹤0.01% | 4324 |
|
|
2024
Q4 | $2.59M | Buy |
+35,000
| New | +$2.45M | ﹤0.01% | 4060 |
|
|
2022
Q1 | – | Sell |
-12,200
| Closed | -$1.58M | – | 6651 |
|
|
2021
Q4 | $1.58M | Sell |
12,200
-67,800
| -85% | -$7.91M | ﹤0.01% | 4448 |
|
|
2021
Q3 | $9.06M | Hold |
80,000
| – | – | ﹤0.01% | 2825 |
|
|
2021
Q2 | $8.29M | Buy |
+80,000
| New | +$7.54M | ﹤0.01% | 2874 |
|
|
2020
Q4 | – | Sell |
-14,700
| Closed | -$1.17M | – | 5535 |
|
|
2020
Q3 | $1.17M | Sell |
14,700
-5,100
| -26% | -$398K | ﹤0.01% | 3962 |
|
|
2020
Q2 | $1.37M | Sell |
19,800
-92,400
| -82% | -$6.57M | ﹤0.01% | 3742 |
|
|
2020
Q1 | $7.05M | Buy |
112,200
+80,700
| +256% | +$5.82M | ﹤0.01% | 2366 |
|
|
2019
Q4 | $2.45M | Sell |
31,500
-9,600
| -23% | -$750K | ﹤0.01% | 3504 |
|
|
2019
Q3 | $3.01M | Buy |
41,100
+34,200
| +496% | +$2.4M | ﹤0.01% | 3232 |
|
|
2019
Q2 | $425K | Sell |
6,900
-110,100
| -94% | -$6.66M | ﹤0.01% | 4463 |
|
|
2019
Q1 | $7.46M | Buy |
117,000
+46,500
| +66% | +$2.65M | ﹤0.01% | 2663 |
|
|
2018
Q4 | $3.6M | Buy |
70,500
+63,600
| +922% | +$3.22M | ﹤0.01% | 3152 |
|
|
2018
Q3 | $400K | Hold |
6,900
| – | – | ﹤0.01% | 4538 |
|
|
2018
Q2 | $335K | Hold |
6,900
| – | – | ﹤0.01% | 4720 |
|
|
2018
Q1 | $321K | Sell |
6,900
-229,500
| -97% | -$9.97M | ﹤0.01% | 4747 |
|
|
2017
Q4 | $8.88M | Buy |
236,400
+209,100
| +766% | +$7.67M | ﹤0.01% | 2548 |
|
|
2017
Q3 | $995K | Sell |
27,300
-1,800
| -6% | -$68.7K | ﹤0.01% | 4573 |
|
|
2017
Q2 | $1.15M | Sell |
29,100
-326,700
| -92% | -$11.9M | ﹤0.01% | 4337 |
|
|
2017
Q1 | $11.2M | Buy |
355,800
+97,200
| +38% | +$3.04M | ﹤0.01% | 2330 |
|
|
2016
Q4 | $8.08M | Sell |
258,600
-116,700
| -31% | -$3.78M | ﹤0.01% | 2630 |
|
|
2016
Q3 | $15.1M | Sell |
375,300
-1,500
| -0.4% | -$56.5K | ﹤0.01% | 2119 |
|
|
2016
Q2 | $12.5M | Buy |
376,800
+278,400
| +283% | +$9.53M | ﹤0.01% | 2141 |
|
|
2016
Q1 | $2.89M | Buy |
98,400
+47,100
| +92% | +$1.3M | ﹤0.01% | 3174 |
|
|
2015
Q4 | $1.35M | Sell |
51,300
-275,700
| -84% | -$7.16M | ﹤0.01% | 4010 |
|
|
2015
Q3 | $7.75M | Buy |
327,000
+292,200
| +840% | +$7.05M | ﹤0.01% | 2472 |
|
|
2015
Q2 | $826K | Sell |
34,800
-259,200
| -88% | -$5.85M | ﹤0.01% | 4709 |
|
|
2015
Q1 | $6.98M | Buy |
294,000
+219,000
| +292% | +$4.91M | ﹤0.01% | 2595 |
|
|
2014
Q4 | $1.59M | Sell |
75,000
-358,800
| -83% | -$7.21M | ﹤0.01% | 4085 |
|
|
2014
Q3 | $7.38M | Sell |
433,800
-533,400
| -55% | -$8.42M | ﹤0.01% | 2641 |
|
|
2014
Q2 | $13.8M | Buy |
967,200
+667,800
| +223% | +$9.05M | ﹤0.01% | 2103 |
|
|
2014
Q1 | $3.7M | Sell |
299,400
-690,000
| -70% | -$7.96M | ﹤0.01% | 3374 |
|
|
2013
Q4 | $10.8M | Sell |
989,400
-582,000
| -37% | -$6.56M | ﹤0.01% | 2302 |
|
|
2013
Q3 | $18.2M | Sell |
1,571,400
-1,596,600
| -50% | -$18.7M | 0.01% | 1698 |
|
|
2013
Q2 | $35.5M | Buy |
+3,168,000
| New | +$37.5M | 0.01% | 1122 |
|
Other funds holding EW
VCM
VPM
Goldman Sachs's EW Position: Q1 2026 in Review
Goldman Sachs increased its Edwards Lifesciences (EW) stake by 54% in Q1 2026, buying an estimated $147M and bringing the position to 5,082,050 shares worth $407M. The position accounts for 0.05% of the portfolio, ranked #404.
Goldman Sachs first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $445M in Q2 2023. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Goldman Sachs held 5,082,050 shares of Edwards Lifesciences worth $407M as of Q1 2026.
- Goldman Sachs bought 1,778,338 Edwards Lifesciences shares in Q1 2026, an estimated $147M.
- Edwards Lifesciences made up 0.05% of Goldman Sachs's portfolio in Q1 2026, its #404 holding.
- Goldman Sachs first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
- Goldman Sachs's Edwards Lifesciences position peaked at $445M in Q2 2023.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.